Reports Q4 revenue $55.2M, consensus $55.27M."We finished the year with 20% revenue growth, driven by both our MRD and Immune Medicine business areas," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "2023 has started strong and I am encouraged to see how momentum is building. We are growing revenue, advancing our pipeline and managing operating expenses with the capital to fuel sustainable growth and execute towards our goals."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
- Adaptive Biotechnologies initiated with an Outperform, $15 target at Scotiabank
- Adaptive Biotechnologies initiated with an Outperform at Scotiabank
- Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
